Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for MDGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2003. Start Trial.
Date Value
December 31, 2025 -189.55M
December 31, 2024 -455.57M
December 31, 2023 -324.23M
December 31, 2022 -224.86M
December 31, 2021 -183.92M
December 31, 2020 -157.56M
December 31, 2019 -41.62M
December 31, 2018 -25.51M
December 31, 2017 -22.32M
December 31, 2016 -17.61M
December 31, 2015 -3.142M
December 31, 2014 -78.92M
Date Value
December 31, 2013 -77.41M
December 31, 2012 -54.14M
December 31, 2011 -47.30M
December 31, 2010 -38.20M
December 31, 2009 -26.81M
December 31, 2008 -37.94M
December 31, 2007 27.22M
December 31, 2006 -52.98M
December 31, 2005 -61.88M
December 31, 2004 -33.80M
December 31, 2003 -23.61M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Exelixis, Inc. 884.27M
Karyopharm Therapeutics, Inc. -75.37M
ACADIA Pharmaceuticals, Inc. 109.84M
Alnylam Pharmaceuticals, Inc. 524.08M
Anika Therapeutics, Inc. 11.19M